CSL Ltd (ASX: CSL) Share Price and News
About CSL
CSL is the ASX's largest healthcare companies, opеrating across ovеr 60 countriеs with more than 26,000 еmployееs. The company is best known for its blood plasma and flu vaccine businesses, but has other products too and undertakes major R&D work.
CSL History
CSL was once a government entity, established in 1916. It was privatised in 1994 at $2.30 a share, although it undertook a three for one share split in 2007 making its IPO price 76.7c in real terms, meaning it has been more than a 300-bagger since listing!
The company's most recent gamble has been to pay US$11.7bn for Swiss company Vifor Pharma. CSL is evidently looking to profit from kidney disease, which affects 850m people globally – a figure expected to grow given the global obesity epidemic. It has faced challenges in justifying this price tag to investors, especially given the rise of Ozempic.
Future Outlook of CSL (ASX: CSL)
CSL has faced an uncertain outlook given the threat of Ozempic, falling margins and skepticism about Vifor. We, however, are confident in the company.
Even if Ozempic could indeed reduce obesity, and with it reduce people developing kidney disease in the future, it would not help people who already have the disease. The cooling of inflation should help its vaccines and blood plasma businesses. And we are also confident in the company's future products.
The company's FY24 and 1H25 results showed the company is relying more on its new medicines including Hemgenix (intended for haemophilia B). To this end, revenue in its Behring division was up 10% whilst revenue from its vaccines business was down 9%.
Is CSL a Good Stock to Buy?
If you want to invest in CSL Ltd (ASX: CSL), you need to have a balanced view of the company's current problems and its future prospects. But all things considered, we think it is a long-term buy.
Even though CSL's share price has dropped a lot since its pre-COVID high, the company is still a leader in the healthcare industry. The company's profit margins are being pushed down, especially in its CSL Behring segment, but they should get better in the medium term.
Cost cuts and possible growth from new products, like Ozempic, and the acquisition of Vifor are expected to bring about this improvement. The company anticipates its profit to be $3.2-3.3bn for FY25 and for revenues to be 5-7% higher. CEO Paul McKenzie proclaimed the company was in a strong position to deliver annualised double-digit earnings growth over the rest of the decade.
Our Stock Analysis
Here are our top 5 contrarian stock ideas on the ASX – is it time to buy?
Many investors are looking for contrarian stock ideas on the ASX. After all, Warren Buffett said to be greedy when…
CSL (ASX:CSL): Its promised double-digit earnings growth for the rest of the 2020s, but will Trump’s tariffs shatter the dream?
CSL has been hit more than most other stocks due to Trump tariffs. While many companies being sold off merely…
How can you find the best stocks for retirement? It starts with looking at these 4 sectors
In this article, we ask the question: how can you find the best stocks for retirement? Investing in stocks can be…
The Top ASX Health Stocks for 2025: Here Are Our 5 Picks!
Here Are Our 5 Top ASX Health Stocks for 2025! Avita Medical (ASX:AVH) OK, first thing’s first. We know this…
3 ASX stocks to buy after Trump’s victory, and 3 ASX stocks to sell
Let’s take a look at 3 ASX stocks to buy after Trump’s victory, and 3 to sell. Last week we…
Your stock needs a moat! Here’s why it is so important
What is a moat? A 20th century dictionary would tell you it is a river surrounding a castle that provided…
Frequently Asked Questions
CSL rеsеarchеs, dеvеlops, manufacturеs, and markеts biothеrapiеs and vaccinеs for rarе and sеrious disеasеs likе blееding disordеrs, immunodеficiеnciеs, and influеnza. Thеy also opеratе thе world's largеst plasma collеction nеtwork